arrow
A

Amir Iravani

Fred Hutchinson Cancer Center
H指数:36
被引数:9,906

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
2025-02-070
PRE
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial

[TheraP研究]:转移性去势抵抗性前列腺癌患者接受[177Lu]Lu-PSMA-617与卡巴他赛治疗疗效反应的预后和预测模型的验证——一项来自随机、开放标签、Ⅱ期临床试验的事后分析

2025-02-013
OAAI
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG-Avid Discordant Findings

基于PET的TheraP资格及VISION试验合格患者中接受177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者的结局:18F-FDG显像不一致结果的重要性

2024-11-141
PRE
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

使用177lu标记的PSMA靶向放射配体疗法 (177Lu-PSMA-RLT) 的EANM/SNMMI联合程序指南

2023-05-2982
OAAI
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0
2022-04-0464
OAAI